Midostaurin: Uses, Side Effects, and How It Works

Midostaurin is an oral cancer drug that works by blocking multiple enzymes called kinases, which cancer cells use to grow and survive. It is approved for two distinct conditions: newly diagnosed acute myeloid leukemia (AML) that carries a specific genetic mutation called FLT3, and advanced systemic mastocytosis, a rare disease driven by abnormal mast cells. The drug’s story and its practical profile are more layered than a simple “cancer pill” label suggests, and both patients and caregivers tend to have questions that go well beyond the label.

How Midostaurin Works

Your body’s cells communicate through signaling proteins called kinases, which act like switches for growth and survival. In certain cancers, those switches get stuck in the “on” position. Midostaurin jams a whole group of these switches at once. It was originally developed as an inhibitor of protein kinase C but turned out to hit a much wider range of targets, including the vascular endothelial growth factor receptor involved in blood vessel formation around tumors.¹ Its ability to block mutant forms of FLT3 and KIT, along with several other kinases involved in leukemia signaling, is what makes it useful in cancer treatment today.²

The FLT3 protein normally helps regulate blood cell production. When the gene encoding it mutates, the protein becomes overactive, essentially telling immature white blood cells to keep multiplying without ever maturing. Roughly a quarter to a third of AML patients have one of these FLT3 mutations. The most common form, FLT3-ITD, involves a stretch of duplicated DNA within the gene. A less common form, FLT3-TKD, is a single-letter change in the gene. Midostaurin blocks both mutant forms, though with somewhat different degrees of effectiveness.³

In mastocytosis, a different kinase mutation causes trouble. Most patients with advanced systemic mastocytosis carry a mutation called KIT D816V, which drives the unchecked accumulation of mast cells in bone marrow, the liver, the spleen, and other organs. Midostaurin blocks the activity of this mutant KIT protein, slowing mast cell growth and reducing the flood of inflammatory chemicals they release.⁴

Treating FLT3-Mutated AML

Midostaurin is not used on its own for AML. It is added to standard intensive chemotherapy (the “7+3” regimen of cytarabine plus an anthracycline) during both the initial induction phase and the follow-up consolidation cycles, then continued as a single agent for up to a year of maintenance. The landmark trial that led to its approval enrolled over 700 patients with FLT3-mutated AML and showed that adding midostaurin to chemotherapy reduced the risk of death by about 22% compared with chemotherapy plus placebo.⁵ That benefit held regardless of whether the patient had an ITD or TKD mutation.

Follow-up analyses of that same trial dug deeper into the relapse question. When researchers looked at relapse rates without factoring in stem cell transplants, patients who received midostaurin had a roughly 29% lower risk of relapse.⁶ However, many patients in the trial went on to receive a stem cell transplant, which itself dramatically reduces relapse risk, making it harder to tease apart exactly how much credit goes to midostaurin versus the transplant.

For the subset of patients with TKD mutations specifically, the picture was more modest. Complete remission rates after induction were similar between the midostaurin and placebo arms, and overall survival differences did not reach statistical significance. There was, however, a meaningful improvement in event-free survival at five years for TKD patients who received midostaurin.⁷ This is worth knowing because it means the drug’s benefit in TKD patients appears to come more from keeping the disease away after initial treatment than from achieving remission in the first place.

Real-World Outcomes Beyond Clinical Trials

Clinical trials have strict entry criteria, so how well does midostaurin perform in everyday practice? Several large registry studies from Europe have now addressed this. A multicenter study from the PETHEMA registry, covering nearly 1,700 adults with FLT3-mutated AML across 129 centers, found that adding midostaurin to intensive chemotherapy pushed the complete remission rate to about 81%, compared with roughly 72% for chemotherapy alone. Median overall survival was substantially longer as well, at about 47 months versus 19 months.⁸ Day-30 mortality was also markedly lower in the midostaurin group, which is a meaningful reassurance given that early death during induction is one of the biggest fears in AML treatment.

A separate multicenter real-world study reported an overall response rate to midostaurin-plus-chemotherapy of about 88%, with a complete remission rate close to 84%. Treatment discontinuation from side effects was low, at about 3.5%.⁹ These numbers are consistent with what the original trial showed, which is reassuring because real-world patients tend to be older, sicker, and more diverse than trial participants.

Older Adults With FLT3-Mutated AML

Age matters a lot in AML treatment. Older patients are more vulnerable to chemotherapy side effects and often have coexisting health problems. There has been genuine uncertainty about whether midostaurin’s benefits extend to patients over 60, since the landmark trial included relatively few of them. A large European study pulling data from three registries specifically addressed this, comparing 194 patients aged 60 and older who received midostaurin plus chemotherapy against 371 who received chemotherapy alone. The results were striking: early death rates by day 60 were substantially lower with midostaurin (about 8% versus 21%), and complete remission rates were higher. Median overall survival was roughly 24 months with midostaurin versus under 9 months without, and five-year survival rates were about 41% versus 13%.¹⁰ These are among the strongest data available for midostaurin in elderly patients, and they suggest the drug is both tolerable and beneficial in this age group.

Advanced Systemic Mastocytosis

Advanced systemic mastocytosis is far rarer than AML, and it comes in several subtypes, including aggressive systemic mastocytosis, mast cell leukemia, and mastocytosis with an associated blood cancer. The disease causes organ damage from the sheer mass of accumulating mast cells and from the chemical mediators they release, leading to symptoms ranging from flushing and severe gastrointestinal trouble to dangerous drops in blood pressure and bone destruction.

In the pivotal trial for this indication, midostaurin produced an overall response rate of 60%, with 45% of patients achieving what is called a major response, meaning at least one type of organ damage resolved completely. Responses were similar regardless of which subtype of advanced mastocytosis the patient had, whether they carried the KIT D816V mutation, or whether they had been treated before.¹¹

Real-world experience has added detail to these numbers. In one series of 13 patients with aggressive disease, about 77% had some clinical benefit. Symptoms tied to mast cell mediator release, like stomach problems, hypotension episodes, allergic reactions, and bone pain, often improved within the first two months. Tryptase levels, a blood marker that tracks mast cell activity, dropped by a median of about 74% within six months, and bone marrow infiltration by mast cells also shrank considerably.¹² That said, some patients progressed very quickly, and three in that same series died within two months. The disease is aggressive by definition, and not everyone responds.

Common Side Effects

Midostaurin’s side-effect profile depends heavily on context. When given alone (as in the maintenance phase for AML or as monotherapy for mastocytosis), it is generally well tolerated. The main complaints are gastrointestinal: nausea, vomiting, and diarrhea, along with fatigue and headache.¹³ Most clinicians prescribe anti-nausea drugs prophylactically before midostaurin doses to keep the GI side effects manageable.

When midostaurin is combined with intensive chemotherapy, however, the picture changes. Blood-related toxicity (low white cells, low platelets, anemia) increases substantially, which is expected given that both chemotherapy and midostaurin suppress the bone marrow.¹⁴ Severe infections and low white cell counts are among the identified risks. Lung-related side effects, including fluid around the lungs and a type of inflammation called interstitial lung disease, have also been documented during the regulatory review of the drug.¹⁵

One side effect worth knowing about is a potential change in heart rhythm. In the AML trial, about 10% of patients receiving midostaurin showed prolongation of the QTc interval on an electrocardiogram, compared with about 6% on placebo. No clinical events (such as dangerous arrhythmias) were linked to these changes, but the finding means your medical team will monitor your heart rhythm during treatment.¹³

Drug Interactions

Midostaurin is broken down in the body primarily by a liver enzyme called CYP3A4, and it also interferes with several other enzymes at the concentrations reached during treatment. That combination makes it a magnet for drug interactions, both as a target and as a disruptor of other drugs’ metabolism.¹⁶

The interaction that matters most in practice involves antifungal drugs. Patients undergoing AML treatment are at high risk of fungal infections and frequently need powerful antifungals like voriconazole or posaconazole, both of which strongly inhibit CYP3A4. Using one of these antifungals alongside midostaurin can roughly 1.4-fold increase midostaurin exposure in the blood.¹⁷ On the flip side, drugs that strongly induce CYP3A4 (certain anti-seizure medications, the antibiotic rifampin) can speed up midostaurin’s breakdown and reduce its effectiveness. The European Medicines Agency flagged interactions with both strong CYP3A4 inhibitors and inducers as important identified risks.¹⁵

In practice, clinicians rarely withhold antifungals from a patient who needs them just because of this interaction. Instead, the approach is to use the antifungal, monitor the patient closely for increased side effects, and adjust if problems arise. The interaction is real but manageable, and skipping antifungal prophylaxis in a severely immunosuppressed patient would be far more dangerous.

How Midostaurin Gets Into Your System

The drug is taken by mouth, typically as two 50-milligram capsules twice daily with food. Absorption from the gut is high, over 90%, and it reaches the bloodstream relatively quickly. Once absorbed, midostaurin binds extremely tightly to proteins in the blood, with over 99% bound at any given time.¹⁸ It is then extensively processed by the liver into two main active metabolites, both of which also inhibit the same kinase targets as the parent drug. Those metabolites can circulate at concentrations even higher than midostaurin itself over time, meaning the drug’s activity lasts well beyond its own breakdown.²

Taking midostaurin with food is not optional advice. High-fat meals improve absorption and help reduce nausea. Missing doses or taking them on an empty stomach can lower drug levels enough to matter, particularly during the critical induction phase of AML therapy.

Resistance and Why the Drug Sometimes Stops Working

Like most targeted cancer therapies, midostaurin can lose effectiveness over time. Resistance can develop through several routes. The cancer may acquire new mutations in FLT3 that change the shape of the protein enough that midostaurin no longer fits well. Alternatively, the cancer cells may activate signaling pathways downstream of FLT3, bypassing the block entirely.¹⁹ The ratio of mutant FLT3 to normal FLT3 in a patient’s leukemia cells can also influence how long the drug works; a higher proportion of mutant copies generally means the cancer is more dependent on that one pathway and, in some cases, more vulnerable to resistance when the drug pressure selects for cells that can escape.

Researchers have explored combining midostaurin with agents that target these downstream escape routes, and that concept underlies some ongoing clinical trials. In practice, if a patient relapses on or after midostaurin, they are usually switched to a next-generation FLT3 inhibitor like gilteritinib, which was designed to be more potent and selective against FLT3.

Where Midostaurin Fits Among Newer FLT3 Inhibitors

Midostaurin was the first FLT3 inhibitor approved for AML, but the field has moved quickly. Gilteritinib, quizartinib, and other agents have since entered clinical use. These newer drugs tend to be more selective for FLT3, whereas midostaurin hits a wider panel of kinases.²⁰ Whether “more selective” translates to “better for patients” is not straightforward. A broad kinase profile can be an advantage if the cancer relies on multiple kinases, but it also means more off-target effects.

Currently, midostaurin is the standard frontline option added to intensive chemotherapy in newly diagnosed FLT3-mutated AML, a position supported by the strong trial and real-world data described above. The newer selective inhibitors have their strongest evidence in the relapsed or refractory setting, meaning patients whose disease came back or did not respond initially. Some trials are now comparing newer agents head-to-head with midostaurin in the frontline setting, which may eventually shift the landscape. For the time being, though, midostaurin remains the drug with the deepest evidence base for newly diagnosed patients starting intensive chemotherapy.

Pediatric Use

Children with FLT3-mutated AML face many of the same biological challenges as adults, and there has been interest in extending midostaurin to younger patients. A phase II trial is underway evaluating midostaurin in pediatric patients using weight-based dosing (30 mg per square meter of body surface area twice daily, or 1 mg per kilogram twice daily for very young children weighing under 10 kilograms) combined with standard chemotherapy and followed by single-agent maintenance. Early data from studies in children with relapsed or refractory disease suggest the drug’s safety profile is consistent with what has been seen in adults, though its efficacy as a single agent in that setting was limited.²¹ The ongoing trial is testing midostaurin in the upfront combined setting, which is how it works best in adults, so more informative results are expected from that design.

Practical Guidance for Patients on Midostaurin

A few things tend to come up repeatedly in clinical practice that are worth knowing if you or someone you care about is starting this drug:

Nausea management: Taking midostaurin with food and using a prescribed anti-nausea medication beforehand makes a real difference. Some clinicians favor ondansetron, while others use olanzapine or lorazepam depending on the patient.
Antifungal coordination: If you need an antifungal like voriconazole or posaconazole, expect your team to monitor you more closely. Do not stop either drug without consulting your doctor.
Heart monitoring: You will likely have electrocardiograms at intervals during treatment. The QTc changes seen in trials were not clinically dangerous, but monitoring is standard.
Dose timing: The twice-daily dosing schedule means roughly 12 hours apart. Consistency helps maintain steady drug levels.
Supplement and herbal caution: St. John’s wort is a strong CYP3A4 inducer and can significantly reduce midostaurin levels. Grapefruit juice inhibits CYP3A4 and can raise them. Both should be avoided unless your medical team says otherwise.

Midostaurin’s practical management in mastocytosis follows similar principles, with the added consideration that mastocytosis patients may have unpredictable episodes of mast cell activation. Clinicians experienced with advanced mastocytosis often start the drug at a time and setting where they can monitor the patient for any initial flare of symptoms as the mast cells begin to respond.²²